Alkermes Plc banner

Alkermes Plc
NASDAQ:ALKS

Watchlist Manager
Alkermes Plc Logo
Alkermes Plc
NASDAQ:ALKS
Watchlist
Price: 34.695 USD -0.62% Market Closed
Market Cap: $5.7B

Relative Value

The Relative Value of one ALKS stock under the Base Case scenario is hidden USD. Compared to the current market price of 34.695 USD, Alkermes Plc is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ALKS Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Multiples Across Competitors

ALKS Competitors Multiples
Alkermes Plc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
IE
Alkermes Plc
NASDAQ:ALKS
5.7B USD 3.8 16.9 11.9 12.9
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 643 258.8 -159 901.4 -194 171.3 -191 955.6
US
Abbvie Inc
NYSE:ABBV
394.1B USD 6.6 167.9 16.3 23.1
US
Amgen Inc
NASDAQ:AMGN
203.3B USD 5.5 26.4 15.1 15.1
US
Gilead Sciences Inc
NASDAQ:GILD
188.3B USD 6.5 23.2 15.8 15.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
119.5B USD 10.2 32.5 23.9 24.9
US
Epizyme Inc
F:EPE
94.1B EUR 2 094 -534.3 -581.8 -566.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
81.8B USD 5.7 18.1 15.4 17.6
AU
CSL Ltd
ASX:CSL
89B AUD 4 20.6 13.8 17.2
NL
argenx SE
XBRU:ARGX
42.4B EUR 14.1 33 56.3 57.9
US
Seagen Inc
F:SGT
39.3B EUR 20.2 -61.8 -66.7 -60.2
P/S Multiple
Revenue Growth P/S to Growth
IE
Alkermes Plc
NASDAQ:ALKS
Average P/S: 3 058 675.4
3.8
7%
0.5
FR
Pharnext SCA
OTC:PNEXF
33 643 258.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.6
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
5.5
2%
2.8
US
Gilead Sciences Inc
NASDAQ:GILD
6.5
4%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.2
10%
1
US
E
Epizyme Inc
F:EPE
2 094
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.7
9%
0.6
AU
CSL Ltd
ASX:CSL
4
5%
0.8
NL
argenx SE
XBRU:ARGX
14.1
49%
0.3
US
S
Seagen Inc
F:SGT
20.2
30%
0.7
P/E Multiple
Earnings Growth PEG
IE
Alkermes Plc
NASDAQ:ALKS
Average P/E: 42.3
16.9
-11%
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -159 901.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
167.9
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
26.4
18%
1.5
US
Gilead Sciences Inc
NASDAQ:GILD
23.2
192%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
32.5
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -534.3 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.1
13%
1.4
AU
CSL Ltd
ASX:CSL
20.6
11%
1.9
NL
argenx SE
XBRU:ARGX
33
42%
0.8
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.8 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IE
Alkermes Plc
NASDAQ:ALKS
Average EV/EBITDA: 21.1
11.9
2%
6
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 171.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.3
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
15.1
10%
1.5
US
Gilead Sciences Inc
NASDAQ:GILD
15.8
7%
2.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.9
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -581.8 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.4
24%
0.6
AU
CSL Ltd
ASX:CSL
13.8
8%
1.7
NL
argenx SE
XBRU:ARGX
56.3
810%
0.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -66.7 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IE
Alkermes Plc
NASDAQ:ALKS
Average EV/EBIT: 23.1
12.9
-9%
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -191 955.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.1
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
15.1
2%
7.5
US
Gilead Sciences Inc
NASDAQ:GILD
15.8
13%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.9
16%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -566.3 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.6
23%
0.8
AU
CSL Ltd
ASX:CSL
17.2
11%
1.6
NL
argenx SE
XBRU:ARGX
57.9
N/A N/A
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.2 N/A N/A